VEGFA and renal cell carcinoma: However, the emergence of targeted therapies, such as vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) and mammalian targets of rapamycin (mTORs), offers promise for improved clinical outcomes in advanced RCC.